Table 1 Baseline characteristics of patients

 Male

12 (46%)

 Female

14 (54%)

Age (years)

73 (45-83)

Prior liver surgery

6 (23%)

Prior bevacizumab

15 (58%)

Lesion volume (ml)

5.8 (1.8–17.57)

Tumoural liver volume (ml)

73 (7.8–201.5)

Non-tumoural liver volume (ml)

1354 (913–4267)

Type of targeting

 Whole liver, common hepatic artery

8 (30%)

 Whole liver, left and right hepatic arteries

6 (23%)

 Uni-lobar

12 (47%)

Delay between predictive and post-treatment dosimetry (days)

9 (6–33)

Net administered activity (MBq)

1262 (675–3314)